BioPharma Dive1h
Biotech startup pulls in $187M to make ‘multi-payload’ ADCs
Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.
Daiichi Sankyo and AstraZeneca report positive result in trial for its gastric cancer treatment
Daiichi Sankyo and AstraZeneca (NASDAQ:AZN) announced that their drug ENHERTU has demonstrated a statistically significant ...
AstraZeneca added to European Conviction List at Goldman Sachs
Goldman Sachs analysts added AstraZeneca (AZN) to the firm’s European Conviction List as part of its monthly update. With 28 Phase-3 readouts ...
Daily12h
AstraZeneca-Daiichi Sankyo Enhertu recommended for approval in EU for patients with HER2-low or HER2-ultralow metastatic breast cancer
Cambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been recommended for approval in the ...